Jio Platforms IPO vs Paras Healthcare IPO: GMP, Price Band, Listing Gain And Which IPO Is Better?

Tomorrow is going to be a big day for IPO investors as two major public issues, the Jio Platforms IPO and Paras Healthcare IPO are going to open for subscription on October 21, 2026.

While Jio Platforms is planning to raise Rs. 30,213 crore, Paras Healthcare is launching a Rs. 1,450-crore IPO. Here is the comparison of both IPOs in terms of size, price band, GMP and more.

Jio Platforms IPO vs Paras Healthcare IPO: Key Details

The Jio Platforms IPO is entirely a fresh issue of 27 crore shares worth Rs. 30,213 crore. In comparison, the Paras Healthcare IPO comprises a fresh issue worth Rs. 500 crore and an offer for sale (OFS) of Rs. 950 crore.

The Jio Platforms IPO price band is Rs. 1,065- Rs. 1,119 per share, while the Paras Healthcare IPO price band is Rs. 660-Rs. 693 per share. The minimum retail investment for Jio Platforms is Rs. 13,428 for a lot of 12 shares. For Paras Healthcare, investors need Rs. 14,553 for a lot of 21 shares.

Both IPOs open on October 21 and close on October 23rd. The allotment is expected on October 26, with tentative listings on the NSE and BSE scheduled for October 28.

Jio Platforms IPO GMP vs Paras Healthcare IPO GMP

According to the data from Investorgain Website, the Jio Platforms IPO GMP stood at Rs. 247 on October 20. Against the upper price band of Rs. 1,119, this indicates an estimated listing price of Rs.1,366 and a potential listing premium of 22.07%.
Meanwhile, the Paras Healthcare IPO GMP was Rs. 75. With an upper price band of Rs. 693, the implied listing price is Rs. 768, indicating an estimated listing gain of 10.82%.

However, GMP is speculative, changes frequently and does not guarantee actual listing gains.

Jio Platforms IPO Review

Canara Bank Securities has recommended subscribing to the Jio Platforms IPO for the long term.

The brokerage in its review noted, "At 33x FY2026 earnings, valuation is at the lower end versus peers. We recommend Subscribe for the long term, given volume-led growth from mobility, homes, and MSMEs, plus ARPU upside from bundled media, productivity, and AI services."

Paras Healthcare IPO Review

Anand Rathi has assigned a "Subscribe Long Term" rating to the Paras Healthcare IPO. According to the brokerage, "Paras Healthcare is valued at 37.7 times annualised FY2027 earnings and 25.73 times FY2026 EBITDA. The IPO fully priced, making valuation an important factor for investors."

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.